49568-65-2

Upstream product

• 1222-71-5 3-(1,2,3,4-tetrahydroxy-butyl)-1H-quinoxalin-2-one 
• 14003-34-0 3-methyl-2-oxo-1,2-dihydroquinoxaline 
• 14003-34-0 3-methylquinoxalin-2-ol 
• 502142-88-3 3-hydroxy-2-dibromomethylquinoxaline 

Downstream Products

• 65780-54-3 3-[(E)-(2-phenylhydrazinylidene)methyl]quinoxalin-2(1H)-one 
• 4188-10-7 3-oxo-3,4-dihydro-quinoxaline-2-carbaldehyde oxime 
• 791068-42-3 (S)-3-[(1-phenyl-ethylamino)methyl]-1H-quinoxalin-2-one 
• 1132669-02-3 3-hydroxyquinoxaline-2-carboxalidene-o-aminophenol 
• 867166-54-9 4-[3-(3-hydroxy-quinoxalin-2-yl)acryloyl]benzoic acid 

Relevant academic research and scientific papers

Synthesis, characterization and biological properties of ruthenium(III) Schiff base complexes derived from 3-hydroxyquinoxaline-2-carboxaldehyde and salicylaldehyde

Ruthenium(III) complexes of the Schiff bases derived from 3-hydroxyquinoxaline-2-carboxaldehyde and o-phenylenediamine, o-aminophenol or 2-aminobenzimidazole (qpd, qap and qab, respectively) and the Schiff bases derived from salicylaldehyde and o-phenylenediamine, o-aminophenol or 2-aminobenzimidazole (salpd, salap and salab, respectively) have been prepared and characterized by elemental, spectral (FT IR, UV-vis, EPR and FAB mass), thermogravimetric, conductance and magnetic moment analyses. The complexes exhibit the following molecular formulae: [Ru2(qpd)Cl 4(H20)2]. 2H2O, [Ru 2(qap)2Cl2(H2O)2]. H 2O, [Ru2(qab)2Cl4(H 2O)2].3H2O, [Ru2(salpd) 3Cl2(H2O)2], [Ru2(salap) 4Cl2]. H2O and [Ru(salab)(H2O) 4]Cl2.H2O. An octahedral structure has been tentatively proposed for all the new complexes. The synthesized ligands and complexes have been tested for in vitro growth inhibitory activity against gram positive bacteria Klebsiella pneumoniae, gram negative bacteria Escherichia coli and Pseudomonas aeruginosa. The complexes are active while the ligands are inactive towards the bacteria under study.

2-PROPENE-1-ONES AS HSP 70 INDUCERS

The present invention relates to novel compounds of 2-propene-1-one series, of general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them, wherein R5, R6, Q and Y are as defined in the specification. The present invention also relates to a process for preparing such compounds, compositions containing such compounds, and use of such compound and composition in medicine. The compounds of the general formula (I) induce HSP-70 and are useful for the treatment of diseases accompanying pathological stress in a living mammalian organism, including a human being, such as stroke, myocardial infarction, inflammatory disorder, hepatotoxicity, sepsis, diseases of viral origin, allograft rejection, tumourous diseases, gastric mucosal damage, brain haemorrhage, endothelial dysfunctions, diabetic complications, neuro-degenerative diseases, post-traumatic neuronal damage, acute renal failure, glaucoma and aging related skin degeneration.

QUINOXALINONE-3- ONE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS

The invention relates to quinoxalinone derivatives of general Formula (I) and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as orexin receptor antagonists.General Formula (I) wherein X and R1-R9 are as defined in the description